Experiments on mice addressed the link between convulsive syndrome and morphological changes in hippocampal neurons occurring on development of pentylenetetrazole (PTZ) kindling. Kindling was induced by i.p. PTZ (35 mg/kg) three times a week for one month. By the end of this period, 70% of the mice responded to administration of PTZ with severe clonic or clonic-tonic seizures. Hippocampal sections (stratum pyramidale, field CA1, Nissl staining) from convulsive mice showed large numbers of altered cells (24.7 ± 2.1%). Most of these were pyramidal neurons. These hyperchromic neurons had reduced body sizes, loss of turgor, wrinkling of the cell body, and deformation of dendritic processes. These dark-type changes were present in 2.3 ± 2.1% of neurons in the hippocampus of intact mice and mice resistant to the convulsogenic effect of PTZ (30% of the population). Immunohistochemical studies demonstrated normal expression of NeuN (Fox3) protein in all hippocampal cells, including dark hyperchromic neurons. This is evidence that neurons did not die en masse and were relatively viable. Prophylactic s.c. administration of NMDA receptor blockers (0.5 mg/kg memantine, 0.1 mg/kg IEM-1921, or 1 mg/kg IEM-1958) decreased the proportion of mice developing PTZ kindling from 70% to 40%. The proportion of altered neurons in the 60% of mice given NMDA blockers and not developing PTZ kindling or convulsions in the presence of blockers was 0.1 ± 0.06%, which was the same as in intact mice. Conversely, the hippocampus of mice demonstrating convulsions despite simultaneous administration of NMDA blockers showed 24.0 ± 5.6% hyperchromic neurons. These results provide evidence that pathologically altered neurons appeared after convulsive seizures in animals after PTZ kindling and that blockade of NMDA glutamate receptors could weaken both the development of convulsive syndrome and the concomitant morphological changes to hippocampal neurons.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
D. S. Vasil’ev, N. L. Tumanova, and I. A. Zhuravin, “Structural changes in the nervous tissue of the neocortex in ontogenesis in rats after hypoxia at different stages of embryogenesis,” Zh. Evolyuts. Biokhim. Fiziol., 44, No. 3, 258–267 (2008).
S. I. Vataev, E. P. Zhabko, N. Ya. Lukomskaya, et al., “Effects of memantine on convulsive reactions and the organization of sleep in Krushinskii–Molodkina rats,” Ros. Fiziol. Zh., 95, No. 8,802–812 (2009).
Yu. M. Zhabotinskii, Normal and Pathological Neuron Morphology, Meditsina, Leningrad (1965).
K. Kh. Kim, A. V. Zaitsev, V. V. Lavrent’eva, et al., “Effects of ionotropic glutamate receptor blockers on pentylenetetrazole convulsions in Krushinskii–Molodkina rats,” Ros. Fiziol. Zh., 98, No. 12, 1520–1529 (2012).
N. Ya. Lukomskaya, S. I. Vataev, E. P. Zhabko, and L. G. Magazanik, “Effects of ionotropic glutamate receptor channel blockers on audiogenic convulsions in Krushinskii–Molodkina rats,” Ros. Fiziol. Zh., 98, No. 4, 449–460 (2012).
N. Ya. Lukomskaya, N. I. Rukoyatkina, L. V. Gorbunova, et al., “Studies of the role of NMDA and AMPA glutamate receptors in the mechanisms of corasol convulsions in mice, “ Ros. Fiziol. Zh., 89, No. 3, 292–301 (2003).
N. Ya. Lukomskaya, N. I. Rukoyatkina, L. V. Gorbunova, et al., “Comparison of the anticonvulsive activities of organic mono- and dications with their ability to inhibit NMDA and AMPA glutamate receptors,” Ros. Fiziol. Zh., 88, No. 9, 1161–1171 (2002).
N. Ya. Lukomskaya, V. V. Lavrent’eva, L. A. Starshinova, et al., “Involvement of ionotropic glutamate receptors in the occurrence of arecoline tremor in mice,” Ros. Fiziol. Zh., 93, No. 3, 275–282 (2007).
N. Ya. Lukomskaya, V. V. Lavrent’eva, L. A. Starshinova, et al., “Effects of ionotropic glutamate receptor channel blockers on the development of pentylenetetrazole kindling in mice,” Ros. Fiziol. Zh., 91, No. 11, 1241–1251 (2005).
T. V. Pavlova, A. A. Yakovlev, M. Yu. Stepanichev, and N. V. Gulyaeva, “Pentylenetetrazole kindling in rats: is neurodegeneration linked with signs of convulsive activity?” Ros. Fiziol. Zh., 91, No. 7, 764–765 (2005).
M. S. Popova,V. A. Aniol, N. A. Lazareva, et al., “Neurodegenerative changes in the hippocampal fields in rats during the development of pentylenetetrazole kindling,” Morfologiya, 142, No. 4, 25–30 (2012).
D. B. Tikhonov and L. G. Magazanik, “Different mechanisms of blockade of ion channels – a pathway to the design of new pharmacological agents,” Ros. Fiziol. Zh., 96, No. 7, 726–739 (2010).
M. M. Ahmed, M. Arif, T. Chikuma, and T. Kato, “Pentylenetetrazole- induced seizures affect the levels of prolyl oligopeptidase, thimet oligopeptidase and glial proteins in rat brain regions, and attenuation by MK-801 pretreatment,” Neurochem. Int., 47, No. 4, 248–259 (2005).
V. A. Aniol, M. Y. Stepanichev, N. A. Lazareva, and N. V. Gulyaeva, “An early decrease in cell proliferation after pentylenetetrazoleinduced seizures,” Epilepsy Behav., 22, No. 3, 433–441 (2011).
R. N. Auer, H. Kalimo, Y. Olsson, and B. K. Siesjo, “The temporal evolution of hypoglycemic brain damage. I. Light- and electronmicroscopic findings in the rat cerebral cortex,” Acta Neuropathol., 67, No. 1–2, 13–24 (1985).
R. N. Auer, H. Kalimo, Y. Olsson, and B. K. Siesjo, “The temporal evolution of hypoglycemic brain damage. II. Light- and electronmicroscopic findings in the hippocampal gyrus and subiculum of the rat,” Acta Neuropathol., 67, No. 1–2, 25–36 (1985).
K. V. Bolshakov, D. B. Tikhonov,V. E. Gmiro, and L. G. Magazanik, “Different arrangement of hydrophobic and nucleophilic components of channel binding sites in N-methyl-D-aspartate and AMPA receptors of rat brain is revealed by channel blockade,” Neurosci. Lett., 291, No. 2, 101–104 (2000).
K. V. Bolshakov,V. E. Gmiro, D. B. Tikhonov, and L. G. Magazanik, “Determinants of trapping block of N-methyl-D-aspartate receptor channels,” J. Neurochem., 87, No. 1, 56–65 (2003).
K. V. Bolshakov, K. H. Kim, N. N. Potapjeva, et al., “Design of antagonists for NMDA and AMPA receptors,” Neuropharmacology, 49, No. 2, 144–155 (2005).
H. S. Chen, J. W. Pellegrini, S. K. Aggarwal, et al., “Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity,” J. Neurosci., 12, No. 11, 4427–4436 (1992).
M. G. Corda, M. Orlandi, D. Lecca, and O. Giorgi, “Decrease in GABAergic function induced by pentylenetetrazole kindling in rats: antagonism by MK-801,” J. Pharmacol. Exp. Ther., 262, No. 2, 792–800 (1992).
D. A. Coulter, D. C. McIntyre, and W. Loscher, “Animal models of limbic epilepsies: what can they tell us?” Brain Pathol., 12, No. 2, 240–256 (2002).
A. Csordas, M. Mazlo, and F. Gallyas, “Recovery versus death of ‘dark’ (compacted) neurons in non-impaired parenchymal environment: light and electron microscopic observations,” Acta Neuropathol., 106, No. 1, 37–49 (2003).
S. C. Danzer, “Depression, stress, epilepsy and adult neurogenesis,” Exp. Neurol., 233, No. 1, 22–32 (2012).
G. De Sarro, E. Palma, N. Costa, et al., “Effects of compounds acting on GABA(B) receptors in the pentylenetetrazole kindling model of epilepsy in mice,” Neuropharmacology, 39, No. 11, 2147–2161 (2000).
A. Dhir, “Pentylenetetrazole (PTZ) kindling model of epilepsy,” Curr. Protoc. Neurosci., Chapter 9, Unit 9.37 (2012).
H. Franke and H. Kittner, “Morphological alterations of neurons and astrocytes and changes in emotional behavior in pentylenetetrazole-kindled rats,” Pharmacol. Biochem. Behav., 70, No. 2–3, 291–303 (2001).
F. Gallyas, A. Csordas, A. Schwarca, and M. Mazlo, “‘Dark’ (compacted) neurons may not die through the necrotic pathway,” Exp. Brain Res., 160, No. 4, 473–486 (2005).
M. Ghasemi and S. C. Schachter, “The NMDA receptor complex as a therapeutic target in epilepsy: a review,” Epilepsy Behav., 22, No. 4, 617–640 (2011).
G. L. Holmes, “Seizure-induced neuronal injury: animal data,” Neurology, 59, No. 9, Suppl. 5, S3–S6 (2002).
R. Q. Huang, C. L. Bell-Horner, M. I. Dibas, et al., “Pentylenetetrazole- induced inhibition of recombinant gamma-aminobutyric acid type A (GABA(A)) receptors: mechanism and site of action,” J. Pharmacol. Exp. Ther., 298, No. 3, 986–995 (2001).
L. W. Jenkins, J. T. Povlishock,W. Lewelt, et al., “The role of postischemic recirculation in the development of ischemic neuronal injury following complete cerebral ischemia,” Acta Neuropathol., 55, No. 3, 205–220 (1981).
W. Jiang, K. Wolfe, L. Xiao, et al., “Ionotropic glutamate receptor antagonists inhibit the proliferation of granule cell precursors in the adult brain after seizures induced by pentylenetetrazole,” Brain Res., 1020, No. 1–2, 154–160 (2004).
B. S. Jortner, “The return of the dark neuron. A histological artifact complicating contemporary neurotoxicologic evaluation,” Neurotoxicology, 27, No. 4, 628–634 (2006).
Z. S. Kherani and R. N. Auer, “Pharmacologic analysis of the mechanism of dark neuron production in cerebral cortex,” Acta Neuropathol., 116, No. 4, 447–452 (2008).
S. E. Kotermanski and J. W. Johnson, “Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer’s drug memantine,” J. Neurosci., 29, No. 9, 2774–2779 (2009).
E. Kovesdi, J. Pal, and F. Gallyas, “The fate of ‘dark’ neurons produced by transient focal cerebral ischemia in a non-necrotic and non-excitotoxic environment: neurobiological aspects,” Brain Res., 1147, 272–283 (2007).
A. M. Lavezzi, M. F. Corna, and L. Matturri, “Neuronal nuclear antigen (NeuN): a useful marker of neuronal immaturity in sudden unexplained perinatal death,” J. Neurol. Sci., 329, No. 1–2, 45–50 (2013).
S. A. Lipton, “Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond,” Nat. Rev. Drug Discov., 5, No. 2, 160–170 (2006).
W. Loscher, “Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy,” Progr. Neurobiol., 54, No. 6, 721–741 (1998).
W. Loscher, “Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy,” Epilepsy Res., 50, No. 1–2, 105–123 (2002).
W. Loscher, “Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs,” Seizure, 20, No. 5, 359–368 (2011).
S. S. Magavi and J. D. Macklis, “Immunocytochemical analysis of neuronal differentiation,” Methods Mol. Biol., 438, 345–352 (2008).
K. Morimoto, M. Fahnestock, and R. J. Racine, “Kindling and status epilepticus models of epilepsy: rewiring the brain,” Progr. Neurobiol., 73, No. 1, 1–60 (2004).
R. J. Mullen, C. R. Buck, and A. M. Smith, “NeuN, a neuronal specific nuclear protein in vertebrates,” Development, 116, No. 1, 201–211 (1992).
M. V. Nikolaev, L. G. Magazanik, and D. B. Tikhonov, “Influence of external magnesium ions on the NMDA receptor channel block by different types of organic cations,” Neuropharmacology, 62, No. 5–6, 2078–2095 (2012).
H. Ooigawa, H. Nawashiro, S. Fufui, et al., “The fate of Nissl-stained dark neurons following traumatic brain injury in rats: difference between neocortex and hippocampus regarding survival rate,” Acta Neuropathol., 112, No. 4, 471–481 (2006).
J. H. Park, H. Cho, H. Kim, and K. Kim, “Repeated brief epileptic seizures by pentylenetetrazole cause neurodegeneration and promote neurogenesis in discrete brain regions of freely moving adult rats,” Neuroscience, 140, No. 2, 673–684 (2006).
C. G. Parsons, W. Danysz, and G. Quack, “Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist – a review of preclinical data,” Neuropharmacology, 38, No. 6, 735–767 (1999).
R. J. Racine, “Modification of seizure activity by electrical stimulation. II. Motor seizure,” EEG Clin. Neurophysiol., 32, No. 3, 281–294 (1972).
M. A. Rogawski, A. Thurkauf, S. Yamaguchi, et al., “Anticonvulsant activities of 1-phenylcyclohexylamine and its conformationally restricted analog 1,1-pentamethylenetetrahydroisoquinoline,” J. Pharmacol. Exp. Ther., 249, No. 3, 708–712 (1989).
R. S. Sloviter, “‘Epileptic’ brain damage in rats induced by sustained electrical stimulation of the perforant path. I. Acute electrophysiological and light microscopic studies,” Brain Res. Bull., 10, No. 5, 675–697 (1983).
R. S. Sloviter and D. W. Dempster, “‘Epileptic’ brain damage is replicated qualitatively in the rat hippocampus by central injection of glutamate or aspartate but not by GABA or acetylcholine,” Brain Res. Bull., 15, No. 1, 39–60 (1985).
T. P. Sutula, J. Hagen, and A. Pitkanen, “Do epileptic seizures damage the brain?” Curr. Opin. Neurol., 16, No. 2, 189–195 (2003).
F. F. Tian, C. Zeng, T. H. Guo, et al., “Mossy fiber sprouting, hippocampal damage and spontaneous recurrent seizures in pentylenetetrazole kindling rat model,” Acta Neurol. Belg., 109, No. 4, 298–304 (2009).
S. F. Traynelis, L. T. Wollmuth, C. J. McBain, et al., “Glutamate receptor ion channels: structure, regulation, and function,” Pharmacol. Rev., 62, No. 3, 405–496 (2010).
G. L. Wenk, C. G. Parsons, and W. Danysz, “Potential role of N methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine,” Behav. Pharmacol., 17, No. 5–6, 411–424 (2006).
M. Wong, D. F. Wozniak, and K. A. Yamada, “An animal model of generalized nonconvulsive status epilepticus: immediate characteristics and long-term effects,” Exp. Neurol., 183, No. 1, 87–99 (2003).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Rossiiskii Fiziologicheskii Zhurnal imeni I. M. Sechenova, Vol. 99, No. 9, pp. 1023–1035, September, 2013.
Rights and permissions
About this article
Cite this article
Vasil’ev, D.S., Tumanova, N.L., Lavrent’eva, V.V. et al. The Ability of NMDA-Type Glutamate Receptor Blockers to Prevent the Development of Pentylenetetrazole Kindling and Morphological Changes to Pyramidal Neurons in the Mouse Hippocampus. Neurosci Behav Physi 45, 528–535 (2015). https://doi.org/10.1007/s11055-015-0106-8
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-015-0106-8